Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
Pooled result · Primary kidney composite, overall populationResult — go to the resultHazard ratio 0.63 95% CI 0.53–0.77Authors' conclusion
These results emphasize a critical role of canagliflozin in kidney protection across a broad spectrum of participants with type 2 diabetes with varying levels of kidney function.
Study context
- Population
- Patients with T2D in the CANVAS Program and CREDENCE trial2 trials pooled · Patients with T2D in the CANVAS Program 10,142 · CREDENCE trial 4,401
- Comparison
- Canagliflozin vs placebo
- Outcome
- Primary kidney composite:
- Doubling of serum creatinine
- End-stage kidney disease
- Renal death
Methodological detailsplacebo-controlled
- Placebo-controlled
Pooled result
Primary kidney composite, overall population
Hazard ratio
0.63
95% CI 0.53–0.77
P < 0.001
Canagliflozinvs Placebo
HR 0.63 (95% CI 0.53–0.77); P < 0.001
As reported in the abstract
Further pooled results
Primary kidney composite by baseline eGFR, albuminuria or KDIGO risk category
- No evidence of heterogeneity in kidney protective effects across subgroups (all pinteraction > .05)
Time to significant risk reduction of primary kidney composite
- Statistically significant risk reduction sustained by ≈18 months after randomization
Original publication
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes Obes Metab. Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →